Flossbach Von Storch SE Invests $9.09 Million in IDEXX Laboratories, Inc. $IDXX

Key Points

• Flossbach Von Storch SE acquired a new $9.09 million position in IDEXX Laboratories during the second quarter, buying 17,270 shares. Institutional investors and hedge funds collectively own 87.84% of the company.
• IDEXX reported quarterly earnings of $4.27 per share, beating estimates of $3.94, while revenue rose 9.7% year over year to $1.22 billion. The company maintained fiscal 2026 guidance of $14.69–$14.94 in EPS.
• Shares recently traded at $562.20, while analysts maintained a “Moderate Buy” consensus with an average price target of $747; recent target changes ranged from $670 to $710.

Flossbach Von Storch SE bought a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 17,270 shares of the company's stock, valued at approximately $9,092,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Aurora Investment Managers LLC. purchased a new stake in IDEXX Laboratories during the 2nd quarter worth approximately $2,442,000. Elyxium Wealth LLC acquired a new position in IDEXX Laboratories in the 4th quarter valued at $3,666,459,000. NewEdge Wealth LLC grew its holdings in shares of IDEXX Laboratories by 122.3% during the fourth quarter. NewEdge Wealth LLC now owns 6,597 shares of the company's stock worth $4,463,000 after buying an additional 3,629 shares in the last quarter. Prospera Financial Services Inc purchased a new stake in shares of IDEXX Laboratories during the fourth quarter worth $4,188,000. Finally, Fortem Financial Group LLC acquired a new stake in shares of IDEXX Laboratories in the fourth quarter valued at about $2,068,000. Hedge funds and other institutional investors own 87.84% of the company's stock.

IDEXX Laboratories Trading Up 1.6%

Shares of IDXX stock opened at $562.20 on Thursday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.17 and a quick ratio of 0.87. The firm has a market cap of $44.29 billion, a PE ratio of 39.54, a price-to-earnings-growth ratio of 2.95 and a beta of 1.54. The company has a 50-day moving average of $560.33 and a two-hundred day moving average of $577.89. IDEXX Laboratories, Inc. has a 1-year low of $518.55 and a 1-year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, beating analysts' consensus estimates of $3.94 by $0.33. The business had revenue of $1.22 billion during the quarter, compared to analysts' expectations of $1.20 billion. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The business's revenue for the quarter was up 9.7% on a year-over-year basis. During the same period last year, the business earned $3.50 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, analysts predict that IDEXX Laboratories, Inc. will post 14.81 EPS for the current year.

Analyst Ratings Changes

Several analysts recently issued reports on IDXX shares. Weiss Ratings raised shares of IDEXX Laboratories from a "hold (c)" rating to a "hold (c+)" rating in a research note on Wednesday, July 29th. Wall Street Zen lowered shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Sunday, July 12th. UBS Group raised their price objective on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 5th. Citigroup boosted their target price on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a "neutral" rating in a report on Wednesday, August 5th. Finally, Barclays cut their price target on shares of IDEXX Laboratories from $800.00 to $710.00 and set an "overweight" rating for the company in a report on Tuesday, August 11th. Six investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $747.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source